Melanoma News and Research

Latest Melanoma News and Research

Salk Institute scientists receive funding for cancer research

Salk Institute scientists Ronald Evans, Diana Hargreaves, Tony Hunter, Graham McVicker and Geoffrey Wahl are among the first wave of researchers to receive funding from Padres Pedal the Cause, one of one of the largest stand-alone cancer fundraising events in San Diego.

27 Jun 2018

New avenue for cancer treatment opens when one drug fails

A new class of cancer drugs – called CDK4/6 inhibitors -- recently approved to treat breast cancer can stunt the cancer's growth and replication.

27 Jun 2018

Phase 1 clinical trial of poliovirus therapy shows long-term survival benefit for recurrent glioblastoma

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, with a three-year survival rate of 21 percent in a phase 1 clinical trial.

26 Jun 2018

Study shows increased risk of cancer among US flight attendants

A new study from Harvard T.H. Chan School of Public Health has revealed that several types of cancer are more common among US flight attendants than they are among the general population.

26 Jun 2018

Novel smart probe may improve post-surgical outcomes for cancer patients

A new Tel Aviv University study explores a novel smart probe for image-guided surgery that may dramatically improve post-surgical outcomes for cancer patients.

26 Jun 2018

Researchers discover immune profile for effective cancer immunotherapy

In a new study published online June 25, 2018 in Nature Medicine, UC San Francisco researchers have identified a key biological pathway in human cancer patients that appears to prime the immune system for a successful response to immunotherapy drugs known as checkpoint inhibitors.

25 Jun 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Ways to reduce your chances of getting skin cancer

Summer is here, but enjoying longer and sunnier days outdoors means your skin is vulnerable to sunburn. Experts at Yale Cancer Center and Yale School of Medicine say unless you take the right precautions, sun exposure (even if you don't get scorched) can damage your skin, causing wrinkles, age spots and even skin cancer. Just one sunburn during your youth doubles your chances of developing melanoma, the deadliest form of skin cancer.

25 Jun 2018

UC Riverside researcher receives grants to advance cancer, ALS research

Maurizio Pellecchia, who holds the Daniel Hays Chair in Cancer Research at the University of California, Riverside, has received two grants to continue his research aimed at finding therapeutics for cancer, amyotrophic lateral sclerosis, and other neurodegenerative diseases.

21 Jun 2018

Protein Data Bank at Rutgers impacts research, education and drug discovery

When Jimmy Carter was diagnosed with end-stage metastatic melanoma in 2015, he began taking a drug developed in part using 3D molecular data.

21 Jun 2018

Summer is good time to check for signs of skin cancer

Summer time means shorts, tank tops, bathing suits – in other words, lots of exposure to the damaging UV rays of the sun. With more skin exposed, now is an especially good time to check for signs of skin cancer.

21 Jun 2018

Researchers uncover new therapeutic opportunity in the treatment of malignant melanoma

A team of researchers led by Dr Pierre Close, WELBIO researcher at the ULiège GIGA Institute and Dr Francesca Rapino has uncovered a new therapeutic opportunity in the treatment of malignant melanoma that acquired resistance to targeted therapies.

21 Jun 2018

Researchers characterize key signaling network that drives growth of triple negative breast cancers

It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy.

20 Jun 2018

Clinical trial targets metastatic colorectal cancer with new combination therapy

Rutgers Cancer Institute of New Jersey is offering a clinical trial targeting an advanced form of colorectal cancer with a combination vaccine/immunotherapy drug treatment.

19 Jun 2018

Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its Phase II clinical trial with drug candidate Namodenoson in the treatment of advanced hepatocellular carcinoma in patients whose disease has progressed on sorafenib therapy.

19 Jun 2018

Scientists discover genetic causes underlying group of related infant cancers

The genetic causes of a group of related infant cancers have been discovered by scientists at the Wellcome Sanger Institute, the University of Wuerzburg and their collaborators.

18 Jun 2018

Vitamin D and Diabetes: What You Need To Know

Dr. Cedric Garland discusses the results of a 12-year cohort study which showed that vitamin D3 can prevent type 1 diabetes in 80 percent of cases.

15 Jun 2018

Study finds higher response to anti-PD1 immunotherapy in older melanoma patients

With each decade of life, the likelihood of progression of melanoma after treatment with anti-PD1 immunotherapy decreased by 13 percent.

13 Jun 2018

Dermatologist gives tips to safely use stick and spray sunscreen

Sunscreen is a vital tool in the fight against skin cancer, including melanoma, the deadliest form.

13 Jun 2018

Older melanoma patients fare better on immune checkpoint blockade therapy

Patient age correlates with response to immunotherapy in melanoma and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute. Study results were published online in Clinical Cancer Research.

13 Jun 2018

Melanoma News and Research

Latest Melanoma News and Research

Salk Institute scientists receive funding for cancer research

New avenue for cancer treatment opens when one drug fails

Phase 1 clinical trial of poliovirus therapy shows long-term survival benefit for recurrent glioblastoma

Study shows increased risk of cancer among US flight attendants

Novel smart probe may improve post-surgical outcomes for cancer patients

Researchers discover immune profile for effective cancer immunotherapy

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Ways to reduce your chances of getting skin cancer

UC Riverside researcher receives grants to advance cancer, ALS research

Protein Data Bank at Rutgers impacts research, education and drug discovery

Summer is good time to check for signs of skin cancer

Researchers uncover new therapeutic opportunity in the treatment of malignant melanoma

Researchers characterize key signaling network that drives growth of triple negative breast cancers

Clinical trial targets metastatic colorectal cancer with new combination therapy

Can-Fite provides update on Phase II clinical trial with drug candidate Namodenoson

Scientists discover genetic causes underlying group of related infant cancers

Vitamin D and Diabetes: What You Need To Know

Study finds higher response to anti-PD1 immunotherapy in older melanoma patients

Dermatologist gives tips to safely use stick and spray sunscreen

Older melanoma patients fare better on immune checkpoint blockade therapy

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Melanoma News and Research

Latest Melanoma News and Research

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in